pp 1–7 | Cite as

Prolactinomas and menopause: any changes in management?

  • Yona GreenmanEmail author



Treatment goals in prolactinomas are to correct hypogonadism, restore fertility and control tumor mass in case of macroadenomas. According to current guidelines, medical treatment of asymptomatic postmenopausal women is not indicated. The purpose of this study was to review the current literature pertaining to biological behavior of prolactinomas during menopause, likelihood of successful dopamine agonist withdrawal during this period and possible prolactin-mediated increased morbidity that could modify current management.


A comprehensive literature search including papers published until July 2019 was conducted using PubMed and Medline databases.


Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years. Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Data directly linking hyperprolactinemia with an increased risk of cancer and cardiovascular and metabolic morbidity are inconsistent. There is no data indicating that correction of hyperprolactinemia improves clinical outcomes in asymptomatic patients bearing microadenomas.


There is no evidence that justifies changing current recommendations to withhold medical treatment of microprolactinomas in asymptomatic post-menopausal women. Macroprolactinoma patients should be treated according to standard clinical practice.


Prolactin Pituitary adenoma Prolactinoma Menopause Osteoporosis Breast cancer 



There was no funding for this paper.

Compliance with Ethical Standards

Conflict of interest

Yona Greenman declares that she has no conflict of interest.

Research involving animal and human participants

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545–553CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382CrossRefGoogle Scholar
  3. 3.
    Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173:655–664CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20–27CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523–1631CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65(4):461–474CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kalleinen N, Polo-Kantola P, Irjala K, Porkka-Heiskanen T, Vahlberg T, Virkki A, Polo O (2008) 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment. J Clin Endocrinol Metab 93(5):1655–1661CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cocks Eschler D, Javanmard P, Cox K, Geer EB (2018) Prolactinoma through the female life cycle. Endocrine 59(1):16–29CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 10:101290CrossRefGoogle Scholar
  10. 10.
    Spark RF, Wills CA, O’Reilly G, Ransil BJ, Bergland R (1982) Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 2:129–132CrossRefGoogle Scholar
  11. 11.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412–418CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J (1996) Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45(3):299–303CrossRefGoogle Scholar
  13. 13.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107PubMedGoogle Scholar
  14. 14.
    Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791–801CrossRefGoogle Scholar
  15. 15.
    Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619CrossRefGoogle Scholar
  16. 16.
    Buurman H, Saeger W (2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753–758CrossRefGoogle Scholar
  17. 17.
    Maor Y, Berezin M (1997) Hyperprolactinemia in postmenopausal women. Fertil Steril 67(4):693–696CrossRefGoogle Scholar
  18. 18.
    Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A (2014) Women with prolactinomas presented at the postmenopausal period. Endocrine 47(3):889–894CrossRefGoogle Scholar
  19. 19.
    Santharam S, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Webster R, Karavitaki N (2017) Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin Endocrinol (Oxf) 87(5):508–514CrossRefGoogle Scholar
  20. 20.
    Balint-Perić LA, Prelević GM (1997) Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. Gynecol Endocrinol 11(4):275–280CrossRefGoogle Scholar
  21. 21.
    Reyes FI, Winter JS, Faiman CI (1977) Pituitary-ovarian relationships preceding the menopause. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 129(5): 557–564.Google Scholar
  22. 22.
    Karunakaran S, Page RC, Wass JA (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 54(3):295–300CrossRefGoogle Scholar
  23. 23.
    Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, Diez S, Fainstein Day P, García-Basavilbaso N, Glerean M, Guitelman M, Katz D, Loto MG, Martinez M, Miragaya K, Moncet D, Rogozinski AS, Servidio M, Stalldecker G, Vitale M, Boero L (2016) Prolactinomas: evolution after menopause. Arch Endocrinol Metab 60(1):42–46CrossRefGoogle Scholar
  24. 24.
    Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Karavitaki N (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf) 89(3):346–353CrossRefGoogle Scholar
  25. 25.
    Indirli R, Ferrante E, Sala E, Giavoli C, Mantovani G, Arosio M (2019) Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm Cancer 10(2–3):120–127CrossRefGoogle Scholar
  26. 26.
    Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. CrossRefGoogle Scholar
  27. 27.
    Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51CrossRefGoogle Scholar
  28. 28.
    Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd (2016) Testosterone and cardiovascular disease. J Am Coll Cardiol 67(5):545–557CrossRefGoogle Scholar
  29. 29.
    Santoro N (2011) Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab 96(11):3281–3288CrossRefGoogle Scholar
  30. 30.
    Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bernard V, Young J, Binart N (2019) Prolactin—a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356–365CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Woodside B (2007) Prolactin and the hyperphagia of lactation. Physiol Behav 91:375–382CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nielsen JH (2016) Beta cell adaptation in pregnancy: a tribute to Claes Hellerström. Upsala J Med Sci 121(2):151–154CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gerardo-Gettens T, Moore BJ, Stern JS, Horwitz BA (1989) Prolactin stimulates food intake in a dose-dependent manner. Am J Physiol 256(1 Pt 2):R276–R280PubMedPubMedCentralGoogle Scholar
  35. 35.
    Perez Millan MI, Luque GM, Ramirez MC, Noain D, Ornstein AM, Rubinstein M, Becu-Villalobos D (2014) Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice. Endocrinology 155:829–839CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Greenman Y, Tordjman Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48(5):547–553CrossRefGoogle Scholar
  37. 37.
    Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, Cakir B (2013) Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44:193–199CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol 79:845–852CrossRefGoogle Scholar
  40. 40.
    Wahlberg J, Tillmar L, Ekman B, Lindahl TL (2013) Effects of prolactin on platelet activation and blood clotting. Scand J Clin Lab Invest 73(3):221–228CrossRefGoogle Scholar
  41. 41.
    Stuijver DJ, Debeij J, van Zaane B, Dekkers OM, Smit JW, Büller HR, Rosendaal FR, Gerdes VE, Cannegieter SC (2012) Levels of prolactin in relation to coagulation factors and risk of venous thrombosis* Results of a large population-based case-control study (MEGA-study). Thromb Haemost 108(3):499–507PubMedGoogle Scholar
  42. 42.
    Faje AT, Klibanski A (2015) The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons. Endocrine 48(1):79–82CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Mon SY, Alkabbani A, Hamrahian A, Thorton JN, Kennedy L, Weil R, Olansky L, Doshi K, Makin V, Hatipoglu B (2013) Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary 16(4):523–527CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, Xu B, Xu M, Chen Y, Bi Y, Wang W, Ning G (2013) Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care 36(7):1974–1980CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Li J, Rice MS, Huang T, Hankinson SE, Clevenger CV, Hu FB, Tworoger SS (2018) Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia 61:2549–2560CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Therkelsen KE, Abraham TM, Pedley A, Massaro JM, Sutherland P, Hoffmann U, Fox CS (2016) Association between prolactin and incidence of cardiovascular risk factors in the framingham heart study. J Am Heart Assoc 5(2):e002640CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT (2009) Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2(4):389–395CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288–293CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4):299–306CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Seriwatanachai D, Krishnamra N, van Leeuwen JPTM (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107:677–685CrossRefGoogle Scholar
  51. 51.
    Klibanski A, Biller BMK, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67(1):124–130CrossRefGoogle Scholar
  52. 52.
    Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73(15):4810–4819CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR (1992) Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 21(2):214–221CrossRefGoogle Scholar
  55. 55.
    Dekkers OM, Ehrenstein V, Bengtsen M, Kormendine Farkas D, Pereira AM, Sørensen HT, Jørgensen JO (2015) Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. EurJ Endocrinol 173:269–273CrossRefGoogle Scholar
  56. 56.
    Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 6:25998CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP (2010) The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 13:195–198CrossRefGoogle Scholar
  58. 58.
    Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6:580–588CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Berinder K, Akre O, Granath F, Hulting A (2011) Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 165:209–215CrossRefGoogle Scholar
  60. 60.
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Endocrinology, Metabolism, Diabetes and HypertensionTel Aviv-Sourasky Medical CenterTel AvivIsrael
  2. 2.Tel Aviv UniversityTel AvivIsrael

Personalised recommendations